| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H23N3O2S |
| Molecular Weight | 393.502 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=CC=C1C2=CC=C(SC3=CC(=CC=C3)C4(CCOCC4)C(N)=O)C=C2
InChI
InChIKey=DVNQWYLVSNPCJZ-UHFFFAOYSA-N
InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
| Molecular Formula | C22H23N3O2S |
| Molecular Weight | 393.502 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
PF-4191834 is a noniron chelating, non-redox inhibitor of the 5-lipoxygenase enzyme (5-LOX) that is being developed as an oral anti-inflammatory therapy for the treatment of asthma. Enzyme assay results demonstrate that PF-4191834 has an improved potency compared with its predecessor CJ-13610 and of zileuton. It was able to reduce pain and inflammation in an adjuvant-induced arthritis model in rats. PF-4191834 offers the potential to test the hypothesis that chronic inhibition of the 5-LOX enzyme will provide maximal efficacy for this target in inflammatory diseases such as asthma, chronic obstructive pulmonary disease, pain, and perhaps lupus. PF-4191834 had been in phase II clinical trial for the treatment of pain. Development was terminated in March 2011.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 229.0 nM [IC50] |
